CoreWeave reported a 112% year-over-year revenue increase in Q1 and a 284% surge in backlog to $99.4 billion, driven by strong demand in AI and tech sectors. Despite some margin pressure due to aggressive expansion and capital expenditures, the company’s growth outlook remains positive. Financial leverage is a concern with a high debt-to-equity ratio of 10.7, suggesting potential future capital raises. The stock remains attractive with a forward price-to-sales ratio of 5.3, supported by sustained demand and differentiation efforts.
Vistra Corp. reported a 20% year-over-year increase in adjusted EBITDA for Q1 2026, driven by improved energy margins and acquisitions. Revenue rose to $5.63 billion with a 26.6% operating margin. The company benefits from long-term power purchase ag...
Johnson & Johnson's nipocalimab, a novel FcRn blocker, met its primary endpoint by significantly reducing disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) at 24 weeks, with benefits sustained through 52 weeks in a...
Johnson & Johnson announced new Phase 2 data for nipocalimab, an immunoselective FcRn blocker, showing greater clinical response in Sjögren's disease patients with elevated autoantibodies and IgG levels. The drug reduced disease activity and symptoms...
SEALSQ has led a €130 million Series A funding round for Quobly, a company developing silicon-based quantum processors, to accelerate industrial deployment of secure quantum computing systems. This investment, made via SEALSQ's Quantum Fund, strength...
Celestica has shifted from low-margin electronics assembly to a high-growth leader in connectivity and cloud solutions, benefiting from hyperscaler capital expenditures and AI infrastructure demand. The company's Q1 results showed 80% year-over-year ...
